FDAapproval95% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Merck; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Renal Cell Carcinoma
- Sub-indication
- General
Related signal: FDA Approves KEYTRUDA Combinations for Adjuvant Treatment in Clear Cell RCC